Funding for this research was provided by:
Canadian Institutes of Health Research (ICT-156651)
Natural Sciences and Engineering Research Council of Canada (NA, NA)
Received: 11 February 2020
Accepted: 23 April 2020
First Online: 6 May 2020
Ethics approval and consent to participate
: All samples were collected and used for research with appropriate written informed consent and with approval by the Health Research Ethics Board of Alberta, the Research Ethics Board of the Hospital for Sick Children (Toronto, ON) and of the CBTTC. Written consent to participate was obtained from the parents or legal guardians of individuals who had not reached the age of majority in their jurisdiction. Written consent to participate was obtained directly from individuals legally considered adults in their jurisdictions.
: Not applicable.
: SWS holds the GlaxoSmithKline-CIHR Chair in Genome Sciences at The Hospital for Sick Children and University of Toronto. SWS is on the Scientific Advisory Committees of Population Bio and Deep Genomics; intellectual property from his research held at the Hospital for Sick Children is licensed to Athena Diagnostics, and separately to Lineagen. These relationships did not influence data interpretation or presentation during this study, but are disclosed for potential future consideration.